Stuttgart - Delayed Quote EUR

Zai Lab Ltd (1ZL.SG)

27.40

-0.40

(-1.44%)

At close: May 2 at 9:26:28 PM GMT+2

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025

SHANGHAI & CAMBRIDGE, Mass., April 25, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data from studies evaluating two of its internally developed, next-generation, investigational oncology therapies that it has global rights to, ZL-6201, a novel leucine-rich repeat-containing protein 15 (LRRC15) antibody-drug conjugate (ADC) targeting multiple solid tumors, and ZL-1222, an innovative anti-PD-1/ interleukin-12 (IL-12) immunocytokine for cancer immunotherapy, during poster sess

Business Wire 8 days ago

ZLAB
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting

SHANGHAI & CAMBRIDGE, Mass., April 23, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating ZL-1310, the Company’s potential first-in-class and best-in-class, Delta-like ligand (DLL3) antibody-drug conjugate (ADC) for the treatment of extensive-stage small cell lung cancer (ES-SCLC), will be presented during a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Mee

Business Wire 10 days ago

ZLAB
Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors

SHANGHAI & CAMBRIDGE, Mass., April 21, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the supplemental New Drug Application (sNDA) for repotrectinib for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. The application is intended for patients whose disease is locally advanced or metastatic, or where surgical resection is likely to re

Business Wire 12 days ago

ZLAB
All You Need to Know About Zai Lab Limited (ZLAB) Rating Upgrade to Buy

Zai Lab Limited (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 18 days ago

ZLAB
Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last?

Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks 19 days ago

ZLAB

BNTX
Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025

SHANGHAI & CAMBRIDGE, Mass., April 14, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its first quarter 2025 financial results and provide recent corporate updates on May 8, 2025, before the opening of the U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT).

Business Wire 19 days ago

ZLAB
Zai Lab Limited (ZLAB): Among Stocks Insiders Sold in April After Trump’s Tariff Rollout

We recently published a list of 10 Stocks Insiders Sold in April After Trump’s Tariff Rollout. In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against other stocks that insiders sold in April after Trump’s tariff rollout. Last week, President Donald Trump signed an executive order imposing […]

Insider Monkey 23 days ago

ZLAB
Spotlight On High Growth Tech Stocks In The US March 2025

Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 5.8% over the past year with earnings forecasted to grow by 14% annually. In this context, identifying high growth tech stocks requires looking for companies that not only show robust revenue potential but also demonstrate resilience and adaptability in fluctuating market conditions.

Simply Wall St. last month

TASK

GMGI

ZLAB
Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting

SHANGHAI & CAMBRIDGE, Mass., March 26, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from preclinical studies of the Company’s internally discovered and developed next-generation, investigational oncology therapies, ZL-6201, an LRRC15 antibody-drug conjugate (ADC) for the treatment of sarcoma, and ZL-1222, a PD-1 targeted IL-12 immunocytokine for cancer immunotherapy, will be presented during poster sessions at the upcoming American Association for Cancer Research (A

Business Wire last month

ZLAB
Is Zai Lab Limited (ZLAB) the Best Performing Growth Stock in 2025?

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against other best performing growth stocks in 2025. Heavy AI investments and the tariffs uncertainty have been putting pressure on the technology and growth sector. […]

Insider Monkey last month

ZLAB
Zai Lab announces acceptance of BLA for TIVDAK in cervical cancer

Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, tisotumab vedotin-tftv, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.” Dr. Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. “Treatment options for patients experiencing recurrence or metastasis after initial treatment are limited. TIVDAK, the

TipRanks last month

ZLAB
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

SHANGHAI & CAMBRIDGE, Mass., March 12, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.

Business Wire last month

ZLAB
Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a Bet

The consensus price target hints at a 64.4% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks last month

ZLAB
Zai Lab Announces Participation in Investor Conferences in March 2025

SHANGHAI & CAMBRIDGE, Mass., March 03, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in March 2025:

Business Wire last month

ZLAB
Zai Lab Limited (NASDAQ:ZLAB) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Investors in Zai Lab Limited ( NASDAQ:ZLAB ) had a good week, as its shares rose 2.5% to close at US$34.64 following...

Simply Wall St. 2 months ago

ZLAB
Zai Lab Full Year 2024 Earnings: Beats Expectations

Zai Lab ( NASDAQ:ZLAB ) Full Year 2024 Results Key Financial Results Revenue: US$399.0m (up 50% from FY 2023). Net...

Simply Wall St. 2 months ago

ZLAB
Zai Lab Ltd (ZLAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Path to Profitability

Zai Lab Ltd (ZLAB) reports a 66% revenue surge in Q4 2024, with strategic advancements paving the way for profitability by late 2025.

GuruFocus.com 2 months ago

ZLAB
China Biotech's Sales Jump 66% But Bottom Line Misses Views

Zai Lab pulled back after the biopharmaceutical reported fourth-quarter results. The biotech is building a cup base.

Investor's Business Daily 2 months ago

ZLAB
Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates

SHANGHAI & CAMBRIDGE, Mass., February 27, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2024, along with recent product highlights and corporate updates.

Business Wire 2 months ago

ZLAB
Is Zai Lab Limited (ZLAB) the Best Performing Mid Cap Stock to Buy According to Analysts?

We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against other best performing mid cap stocks to buy according to analysts. On February 7, Simeon Hyman, Global Investment Strategist at […]

Insider Monkey 2 months ago

ZLAB

^GSPC

Performance Overview

Return	1ZL.SG	HANG SENG INDEX (^HSI)
YTD	+7.87%	+12.19%
1-Year	+85.14%	+23.60%
3-Year	-33.17%	+6.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Zai Lab Ltd (1ZL.SG)

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting

Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors

All You Need to Know About Zai Lab Limited (ZLAB) Rating Upgrade to Buy

Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last?

Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025

Zai Lab Limited (ZLAB): Among Stocks Insiders Sold in April After Trump’s Tariff Rollout

Spotlight On High Growth Tech Stocks In The US March 2025

Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting

Is Zai Lab Limited (ZLAB) the Best Performing Growth Stock in 2025?

Zai Lab announces acceptance of BLA for TIVDAK in cervical cancer

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a Bet

Zai Lab Announces Participation in Investor Conferences in March 2025

Zai Lab Limited (NASDAQ:ZLAB) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Zai Lab Full Year 2024 Earnings: Beats Expectations

Zai Lab Ltd (ZLAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Path to Profitability

China Biotech's Sales Jump 66% But Bottom Line Misses Views

Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates

Is Zai Lab Limited (ZLAB) the Best Performing Mid Cap Stock to Buy According to Analysts?

Performance Overview